Eris Life eyes top end pricing for Rp17bn IPO
Eris Lifesciences is set to price its Indian IPO at the top of guidance to raise Rp17.4bn ($269.3m), after books closed multiple times subscribed, according to a banker on the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: